ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: These findings suggest that the T9141-TCR can specifically target CML leukemic cells that highly express the ABL-E255V-neoepitope, thus benefiting patients who are resistant to available TKIs due to E255V-involved compound mutations.